Using inverse-weighting in cost-effectiveness analysis with censored data (Q5424166): Difference between revisions

From MaRDI portal
RedirectionBot (talk | contribs)
Changed an Item
ReferenceBot (talk | contribs)
Changed an Item
 
(3 intermediate revisions by 3 users not shown)
Property / MaRDI profile type
 
Property / MaRDI profile type: MaRDI publication profile / rank
 
Normal rank
Property / full work available at URL
 
Property / full work available at URL: https://doi.org/10.1191/0962280202sm308ra / rank
 
Normal rank
Property / OpenAlex ID
 
Property / OpenAlex ID: W2057830194 / rank
 
Normal rank
Property / Wikidata QID
 
Property / Wikidata QID: Q30760278 / rank
 
Normal rank
Property / cites work
 
Property / cites work: Estimating Medical Costs from Incomplete Follow-Up Data / rank
 
Normal rank
Property / cites work
 
Property / cites work: Linear regression analysis of censored medical costs / rank
 
Normal rank
Property / cites work
 
Property / cites work: Estimating medical costs with censored data / rank
 
Normal rank
Property / cites work
 
Property / cites work: A regression-based method for estimating mean treatment cost in the presence of right-censoring / rank
 
Normal rank
Property / cites work
 
Property / cites work: On Estimating Medical Cost and Incremental Cost-Effectiveness Ratios with Censored Data / rank
 
Normal rank
Property / cites work
 
Property / cites work: A consistent estimator for the distribution of quality adjusted survival time / rank
 
Normal rank
Property / cites work
 
Property / cites work: Efficient Estimation of the Distribution of Quality‐Adjusted Survival Time / rank
 
Normal rank
Property / cites work
 
Property / cites work: Testing Equality of Survival Functions of Quality-Adjusted Lifetime / rank
 
Normal rank

Latest revision as of 12:29, 27 June 2024

scientific article; zbMATH DE number 5208013
Language Label Description Also known as
English
Using inverse-weighting in cost-effectiveness analysis with censored data
scientific article; zbMATH DE number 5208013

    Statements